Search

We all know company brands - Coca-Cola, Nike, McDonald’s. But we rarely talk about country brands. And the U.S. and China are waging a huge brand war.

Fertilizer stocks may not be the most glamorous option, but they’re a great inflation play. Here are three that are making a big move.

This month we’re adding a high-growth biotech name that has just begun to commercialize a unique compound for fighting aggressive cancers and other diseases including, potentially, COVID-19.

The company just began booking revenue from its first cancer treatment. That launch significantly de-risks the stock and raises the potential for future approval of the same compound for other indications.



The stock has retreated lately because prescription sales were curbed during the COVID-19 outbreak. This should be a temporary dip as there are many potential stock-moving catalysts coming this year. We’re hoping to sneak in and buy the dip on this high-potential name.



All the details are inside this month’s Issue. Enjoy!

For anyone engaged in the forecasting business, the temptation is always present to make a sensational claim about the future in order to stand out from the crowd and garner mainstream media attention. And truth be told, for those of us whose livelihoods involve predicting financial markets, that temptation must often be suppressed in the interest of professionalism.

Stocks seemed to wobble a bit this week and yesterday there was a mild sell-off among some tech stocks. Still, of the 400 S&P 500 companies that have already reported earnings, 80% had beaten analysts’ expectations, according to FactSet. Overall, the Explorer portfolio has performed relatively well with Fisker (FSR) up 17% and Virgin Galactic (SPCE) doubling since the beginning of 2021. This week’s new recommendation is from a sector in an uptrend due to a combination of higher demand and tight supply.

A tough week for markets as concerns over recession, persistent inflation, and geopolitical tensions grow. Explorer stocks were not spared as they all pulled back with exception of Oracle (ORCL) and micro-cap Kraken Robotics (KRKNF). New restrictions on chip-related sales to China hit semiconductor stocks. An almost $8 billion deal by Brookfield Renewable Partners and uranium producer Cameco to buy nuclear services firm Westinghouse is the latest sign of revival in nuclear power after years of decline. The matchup would create something of a Western nuclear powerhouse, pairing a key nuclear power service provider with the largest publicly traded uranium company and one of the world’s biggest owners of wind and solar projects.

This week we sell two positions and go to Japan for a conservative, high quality play on an overlooked but critical part of the electric vehicle revolution.

Ford (F) reported a down third quarter, but Explorer stocks had a good week with all positions in the black. MP Materials (MP) and Oracle (ORCL) were up 11%, and SQM rose 8%.

The headline of today’s GDP report will likely be more upbeat than the two previous negative growth numbers, instead showing that third-quarter GDP grew at about a 2% annualized pace.

But beneath these numbers, investor sentiment, economic trends, and geopolitical risks are not all that encouraging.

How should investors take all this in and execute a strategy to exploit the situation?

Recent trends in rising oil prices provide plenty of investment opportunities.

Want to know the best dividend stocks for 2018? Focus on factors that will attract more investors to the stock short-term. Here are five that fit that mold.

The little stories fill in the blanks behind the government-sanctioned news.

Patriots quarterback Tom Brady has teamed with with Deckers Outdoor to sell UGGs.

My career at Cabot began back in June 1999, just before the internet bubble really revved up in October. That was a time of great divergences—the broad market struggled all the way from the mini-bear market bottom of October 1998 right through the top in March 2000. Today I see a similar dichotomy in the market—many “old” leaders are struggling while “new” growth concepts are finding support.

My approach to investing is conservative; the tortoise wins the race. But the race is only won over an extended period of time where cultivating patience is an absolute necessity. My objective is to stay fully invested at all times in stocks and bonds, and only invest in stocks and bonds that will decline a minimal amount during stock market corrections.

Last week, I wrote about the automotive aspects of my recent road trip from Salem to Savannah and back.

Mere weeks after its failed merger with Pfizer (PFE), global pharmaceutical company Allergan PLC (AGN), maker of Viagra and Botox, announced a new $10 billion share repurchase authorization. Allergan plans to complete the $40 billion sale of its generic pharmaceutical business to Teva Pharmaceuticals by the end of this month. Following that, Allergan plans to immediately repurchase $4 billion to $5 billion of its stock over the subsequent four to six months. The company also plans to pay down debt with the proceeds of the Teva transaction. Let’s look at the stock’s valuation to see if it’s worth investing in.